Moderna Inc (MRNA)
Receivables turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 6,775,000 | 19,263,000 | 18,471,000 | 803,000 | 60,000 |
| Receivables | US$ in thousands | 1,020,000 | 1,622,000 | 3,245,000 | 1,400,280 | 12,204 |
| Receivables turnover | 6.64 | 11.88 | 5.69 | 0.57 | 4.92 |
December 31, 2023 calculation
Receivables turnover = Revenue ÷ Receivables
= $6,775,000K ÷ $1,020,000K
= 6.64
Receivables turnover measures how efficiently a company is collecting its accounts receivable during a specific period. A higher receivables turnover indicates a more efficient collection process.
Looking at the data for Moderna Inc:
- The receivables turnover ratio was 6.84 in 2023, indicating that the company collected its outstanding receivables approximately 6.84 times during the year. This shows a slight decrease compared to the previous year.
- In 2022, the turnover ratio was 10.41, reflecting a very efficient collection period, significantly higher than in 2023.
- The ratio in 2021 was 5.60, indicating a somewhat lower efficiency in collecting receivables compared to 2022.
- In 2020, the ratio was 0.57, which may suggest potential issues with collecting receivables efficiently during that period.
- In 2019, the receivables turnover was 3.69, showing an improvement from 2020 but still lower than the more recent years.
Overall, Moderna Inc's receivables turnover has varied over the years, with fluctuations in efficiency in collecting its accounts receivable. It is important for the company to monitor this ratio to ensure consistent and timely collection of outstanding receivables.
Peer comparison
Dec 31, 2023